Table 2.
Correlations of plasma adipokine concentrations with clinical and echocardiographic parameters in patients with CAD (Spearman rank correlation coefficients).
| Correlated Parameters |
Adiponectin | Leptin | Resistin | |||
|---|---|---|---|---|---|---|
| Rs | p-Value | Rs | p-Value | Rs | p-Value | |
| Age | 0.36 | 0.0000018 | 0.12 | 0.12 | 0.06 | 0.47 |
| NYHA | 0.22 | 0.0039 | 0.19 | 0.016 | 0.09 | 0.26 |
| CCS | 0.17 | 0.028 | 0.04 | 0.58 | 0.07 | 0.39 |
| Number of MI | 0.03 | 0.67 | 0.05 | 0.56 | 0.14 | 0.074 |
| BMI | −0.08 | 0.30 | 0.51 | <0.000001 | 0.02 | 0.83 |
| HR | 0.13 | 0.091 | 0.13 | 0.085 | −0.02 | 0.80 |
| SBP | 0.15 | 0.052 | 0.20 | 0.010 | 0.00 | 0.96 |
| DBP | 0.08 | 0.31 | 0.22 | 0.0037 | −0.01 | 0.86 |
| BNP | 0.39 | 0.0000002 | −0.01 | 0.84 | 0.01 | 0.88 |
| LVMI | 0.06 | 0.47 | −0.03 | 0.67 | 0.13 | 0.10 |
| LVEDV | 0.07 | 0.37 | −0.08 | 0.28 | 0.06 | 0.47 |
| LVEDVBSA | 0.15 | 0.049 | −0.14 | 0.07 | 0.07 | 0.35 |
| LVEDD | 0.09 | 0.26 | −0.08 | 0.29 | 0.02 | 0.83 |
| LVEDDBSA | 0.26 | 0.00057 | −0.17 | 0.026 | 0.05 | 0.54 |
| LVESD | 0.14 | 0.078 | −0.04 | 0.65 | 0.06 | 0.48 |
| IVSd | −0.10 | 0.19 | 0.08 | 0.31 | 0.14 | 0.063 |
| PWd | −0.08 | 0.32 | 0.04 | 0.61 | 0.01 | 0.92 |
| Ao | −0.13 | 0.087 | −0.16 | 0.042 | −0.05 | 0.50 |
| LAD | 0.13 | 0.089 | 0.08 | 0.29 | 0.01 | 0.89 |
| RVEDD | 0.02 | 0.79 | 0.08 | 0.33 | 0.06 | 0.42 |
| RVSP | 0.23 | 0.089 | −0.02 | 0.90 | 0.05 | 0.69 |
| LVEF | −0.20 | 0.0093 | 0.02 | 0.78 | −0.06 | 0.45 |
| LVSF | −0.17 | 0.025 | −0.01 | 0.89 | −0.09 | 0.27 |
| E/A | 0.11 | 0.18 | −0.06 | 0.46 | −0.17 | 0.034 |
| DT | −0.14 | 0.072 | −0.03 | 0.75 | −0.04 | 0.64 |
| IVRT | −0.15 | 0.057 | −0.21 | 0.0080 | −0.02 | 0.80 |
| TEI | −0.03 | 0.72 | −0.20 | 0.014 | 0.09 | 0.28 |
| Vp | −0.14 | 0.083 | 0.09 | 0.28 | −0.03 | 0.75 |
| MR | 0.32 | 0.000035 | 0.01 | 0.91 | −0.03 | 0.72 |
Significant correlations (p < 0.05) are marked in bold. Abbreviations: Ao—ascending aorta diameter; BNP—plasma brain natriuretic peptide; CCS—severity of CAD symptoms evaluated by the Canadian Cardiovascular Society Angina Grading Scale; DBP—diastolic blood pressure; DT—mitral valve deceleration time; E/A—mitral valve E/A ratio; HR—heart rate beats/min; IVRT—isovolumetric relaxation time; IVSd—intraventricular septal end-diastolic thickness; LAD—left atrium diameter; LVEDD—left ventricular end-diastolic diameter; LVEDDBSA—left ventricular end-diastolic diameter/body surface area; LVEDV—left ventricular end-diastolic volume; LVEDVBSA—left ventricular end-diastolic volume/body surface area; LVEF—left ventricular ejection fraction; LVESD—left ventricular end-systolic diameter; LVMI—left ventricular mass index; LVSF—left ventricular shortening fraction; MI—myocardial infarction; MR—grade of mitral regurgitation, NYHA—severity of heart failure evaluated by the New York Heart Association functional classification; PWd—posterior wall end-diastolic thickness; RVEDD—right ventricular end-diastolic diameter; RVSP—right ventricular systolic pressure; SBP—systolic blood pressure; TEI—Tei index; Vp—propagation velocity.